Candel Therapeutics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data and as it prepares for a planned biologics license application submission by the end of the year.
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, 2026...
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific
Extended follow-up data from the phase 3 study confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival of 39% after...
Presentation Operator MessageOperator Good afternoon, and welcome to the Candel Therapeutics conference call, where the company will be discussing extended follow-up data from the Phase III
AUA Investor Call Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer ...
Tipping the balance in favor of the immune system to fight cancer Corporate...
Candel Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 8.86 million compared to net income of USD...
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.34) by 58.82 percent. This is a 207.69 percent decrease over earnings of $0.13 per share
Company plans to submit a Biologics License Application for aglatimagene besadenovec in localized, intermediate- to high-risk prostate cancer in Q4 2026Announced purpose-built commercial partnership...
NEEDHAM, Mass., May 13, 2026 -- Candel Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with...
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced
Conference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET NEEDHAM, Mass., May 04, 2026 -- Candel Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing...
NEEDHAM, Mass., May 01, 2026 -- Candel Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients with cancer,...
Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a global commercialization services provider, to gear up for the potential US launch of...
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 --...
Candel Therapeutics, Inc. could surge as aglatimagene nears Phase 3 prostate cancer readouts and a BLA; click to explore CADL stock upside, risks, and more.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 10.99M | $53.84M | 0.00% | Added+33.4% | 2026-03-31 |
| StateStreet | passive | 818.6K | $4.01M | 0.00% | Added+3.3% | 2026-03-31 |
| Citadel | multi-strat | 107.2K | $525.33K | 0.00% | New | 2026-03-31 |
| TwoSigma | quant | 93.5K | $458.15K | 0.00% | Trimmed-5.7% | 2026-03-31 |
| RenTech | quant | 12.8K | $62.62K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 30.1K | $148 | 0.00% | Added+16.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.26 | — | — |
| 2026-05-14 | -0.33 | -0.14 | +57.06% |
| 2026-03-12 | -0.23 | -0.29 | -23.83% |
| 2025-11-13 | -0.16 | -0.23 | -37.09% |
| 2025-08-14 | -0.17 | -0.20 | -16.57% |
| 2025-05-13 | -0.24 | -0.14 | +42.92% |
| 2025-03-13 | -0.23 | -0.23 | -0.65% |
| 2024-03-28 | -0.16 | -0.38 | -137.50% |
| 2023-11-09 | -0.19 | -0.29 | -52.63% |
| 2023-08-10 | -0.37 | -0.33 | +10.81% |
| 2023-05-11 | -0.35 | -0.30 | +14.29% |
| 2023-03-30 | -0.39 | -0.26 | +32.71% |
| 2022-11-10 | -0.36 | -0.31 | +13.05% |
| 2022-08-05 | -0.43 | -0.32 | +27.24% |
| 2022-05-12 | -0.31 | -0.32 | -3.97% |
| 2022-03-29 | -0.24 | -0.21 | +11.04% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CADL | +28.28% | +69.04% | +46.90% | +52.29% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +25.32% | +73.68% | +50.35% | +39.61% |